Seelos Therapeutics shares are trading lower after the company announced its SLS-002 Phase II study did not meet the pre-defined primary endpoint due to limited sample size.
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics announced that its SLS-002 Phase II study did not meet the pre-defined primary endpoint due to limited sample size, causing its shares to trade lower.
September 20, 2023 | 12:57 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Seelos Therapeutics' stock is trading lower after the company's SLS-002 Phase II study did not meet its primary endpoint due to limited sample size.
The failure of a clinical trial, especially one in Phase II, is often seen as a significant setback for a pharmaceutical company. This is because it indicates that the drug may not be as effective as initially thought, which can lead to a decrease in investor confidence and a subsequent drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100